HMPL-453 + Rabeprazole
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intrahepatic Cholangiocarcinoma
Conditions
Intrahepatic Cholangiocarcinoma
Trial Timeline
Mar 17, 2023 → Aug 28, 2023
NCT ID
NCT05930119About HMPL-453 + Rabeprazole
HMPL-453 + Rabeprazole is a phase 1 stage product being developed by HUTCHMED for Intrahepatic Cholangiocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05930119. Target conditions include Intrahepatic Cholangiocarcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05930119 | Phase 1 | Completed |
Competing Products
20 competing products in Intrahepatic Cholangiocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Apatinib and Adebrelimab in Combination With chemotherapy | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Camrelizumab + Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Durvalumab + SNDX-6352 | AstraZeneca | Phase 2 | 52 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| Pemigatinib + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Durvalumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 52 |
| Pemigatinib | Incyte | Phase 2 | 49 |
| A4250 (odevixibat) | Ipsen | Phase 3 | 74 |
| Odevixibat | Ipsen | Pre-clinical | 20 |
| CGT4859 | Cogent Biosciences | Phase 1/2 | 38 |
| LUM001 (Maralixibat) | Mirum Pharmaceuticals | Phase 2 | 49 |
| Maralixibat | Mirum Pharmaceuticals | Phase 3 | 74 |
| Maralixibat | Mirum Pharmaceuticals | Phase 2 | 49 |
| Maralixibat | Mirum Pharmaceuticals | Phase 2 | 49 |
| Volixibat + Placebo | Mirum Pharmaceuticals | Phase 2 | 49 |
| Maralixibat | Mirum Pharmaceuticals | Phase 3 | 74 |
| Maralixibat + Placebo | Mirum Pharmaceuticals | Phase 3 | 74 |